Relevance of Patient-Reported Outcomes for the Management of Patients with Inflammatory Bowel Disease

This webinar took place on 5th October 2016, broadcast from London, UK

Speaker: Axel Dignass

Department of Medicine I-Gastroenterology, Hepatology, Oncology and Metabolism,
Agaplesion Markus Hospital and Goethe-University, Frankfurt, Germany

Disclosure: Prof Dr Axel Dignass has received grants/research support from the Institut für Gemeinwohl and Stiftung Leben mit Krebs, and honoraria or consultation fees from AbbVie, MSD, Ferring, Roche/Genentech, Takeda, Pharmacosmos, Holystone Biotech, Falk, Mundipharma, Toray, Allergosan, Hospira, Robarts, TFS Trial Support, and Sandoz/Hexal. He has participated in company-sponsored speaker’s bureaus for the
Falk Foundation, Ferring, MSD, AbbVie, Otsuka, Vifor, Immundiagnostik, Janssen-Cilag, Med Update GmbH, Medice, CED Service GmbH, and Mundipharma. He has received payment for manuscript preparation from the Falk Foundation, Wiley, and Thieme, and payment for educational presentations from Pharmacosmos, the Falk Foundation, Ferring, Takeda, and Tillotts Pharma AG.
Acknowledgements: Writing assistance was provided by Morgan McKenzie of Ashfield Healthcare Communications Ltd.
Support: The publication of this article was funded by Tillotts Pharma AG. The webinar was an independent educational event sponsored by Tillotts Pharma AG, and the views and opinions expressed are those of the speakers and not necessarily of Tillotts Pharma AG. Tillotts Pharma AG had no influence over the content of this article or the webinar on which it was based.
Citation: EMJ Gastroenterol. 2016;5[1]:43-48.

Meeting Summary

Patient adherence is a major problem in the treatment of inflammatory bowel disease (IBD). Research has shown that improved patient adherence and outcomes can be achieved if physicians are able to dedicate more time and attention to analysing patients’ feedback on their healthcare. The US Food and Drug Administration (FDA) has defined patient-reported outcomes (PROs) as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else.” Such patient reports may include various symptoms that are not obvious or that occur in the absence of an observer; they may describe the frequency and severity of a symptom, and the impact that it has on day-to-day life. They can describe factors such as patient satisfaction, productivity, use of resources, and health-related quality of life (QoL).

Interestingly, PROs do not always correlate with the physician’s view. Evidence has shown that physicians often underestimate the severity of a patient’s illness, report fewer problems than patients, and overestimate the improvements of treatment. In order to improve the value of PROs, physicians must engage patients in their disease management, otherwise known as patient empowerment. Empowerment can improve treatment success.

As it is becoming clearer that empowered and informed patients who are able to have a role in the decision-making have better outcomes, PROs will not only have further impact on the management of patients with IBD but also on health technology assessments and healthcare payer decisions.

Click here to view the full webinar.

This article has a correction, made on 15.12.16.
The details of the correction are as follows: The reference order has been updated.
The prior version of the paper is available on request, please contact editor@emjreviews.com

Download (PDF, 118KB)

Comments are closed.